



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

*In re* Application of: )  
Schneck et al. ) GAU: 1643  
Serial No.: 09/642,660 ) Examiner: Christopher H. Yaen  
Filed: August 22, 2000 ) Docket No. 001107.00042

For: **CELL COMPOSITIONS COMPRISING MOLECULAR COMPLEXES  
THAT MODIFY IMMUNE RESPONSES**

**INFORMATION DISCLOSURE STATEMENT**

U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, enclosed are two PTO Forms-1449 listing documents for consideration by the Examiner during the prosecution of the subject application.

Please charge our Deposit Account No. 19-0733 in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for the filing fee.

Respectfully submitted,

Dated: January 11, 2006

By: Lisa M. Hemmendinger  
Lisa M. Hemmendinger  
Registration No. 42,653

Customer No. 22907

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	09/642,660
Filing Date	August 22, 2000
First Named Inventor	Schneck
Group Art Unit	1643
Examiner Name	Christopher H. Yaen
Attorney Docket Number	001107.00042

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		5,583,031	12-10-1996	Stern	
		6,015,884	1-18-2000	Schneck <i>et al.</i>	
		6,140,113	10-31-2000	Schneck <i>et al.</i>	
		6,269,411	07-31-2001	Reasoner	
		6,448,071	9-10-2002	Schneck <i>et al.</i>	
		6,458,354	10-1-2002	Schneck <i>et al.</i>	
		6,268,411	7-31-2001	Schneck <i>et al.</i>	
		6,787,154	09-07-2004	Albani	
		US 2002/0119121	8-29-2002	Vitiello <i>et al.</i>	
		US 2002/0122818	9-5-2002	Albani	
		US 2003/0077248	4-24-2003	Moriarty <i>et al.</i>	
		Serial No. 09/642,660	unpublished	Schneck <i>et al.</i>	
		2002/0006903	1-17-2002	Schneck <i>et al.</i>	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		WO 01/94944	December 13, 2001	Memorial Sloan-Kettering Cancer Center		
		WO 00/40968	07-13-2000	Hindustan Lever Limited		
		WO 01/80833	11/01/2001	Salvatore Albani		
		WO 02/065992	08/29/2002	Ortho-McNeil Pharmaceutical, Inc.		
		WO 03/057171	07/17/2003	The Trustees of the University of Pennsylvania		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/642,660
Filing Date	August 22, 2000
First Named Inventor	Schneck
Group Art Unit	1643
Examiner Name	Christopher H. Yaen
Attorney Docket Number	001107.00042

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Goldberg <i>et al.</i> , "In vivo Augmentation of Tumor-Specific CTL Responses by Class I/Peptide Antigen Complexes on Microspheres (Large Multivalent Immunogen)," <i>J. Immunol.</i> 170, 228-35, 2003	
		Latouche & Sadelain, "Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells," <i>Nature Biotechnol.</i> 18, 405-09, April 2000	
		Levine <i>et al.</i> , "Effects of CD28 Costimulation on Long-Term Proliferation of CD4+ T cells in the Absence of Exogenous Feeder Cells," <i>J. Immunol.</i> 159, 5921-30, 1997	
		Maus <i>et al.</i> , "Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB," <i>Nature Biotechnol.</i> 20, 143-48, February 2002	
		Maus <i>et al.</i> , "HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells," <i>Clin. Immunol.</i> 106, 16-22, 2003	
		NAKAMURA <i>et al.</i> , "Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , Vol. 8, No. 8, August 2002, pp 2742-2749.	
		OELKE <i>et al.</i> , "Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells," <i>Nature Medicine</i> , Vol. 9, No. 5, May 2003, pp 619-624.	
		OELKE <i>et al.</i> , "Generation and purification of CD8 <sup>+</sup> melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy," <i>Clinical Cancer Research: An Official Journal of the American Association for Cancer Research</i> , May 2000, Vol. 6, No. 5, pp 1997-2005.	
		VON BERGWELT-BAILDON <i>et al.</i> , "Human primary and memory cytotoxic T lymphocyte responses are effectively induced by means of CD40-activated B cells as antigen-presenting cells: Potential for clinical application," <i>Blood</i> , Vol. 99, No. 9, May 1, 2002, pp 3319-3325.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.